Compare · ANCN vs DRNA
ANCN vs DRNA
Side-by-side comparison of Anchiano Therapeutics Ltd. (ANCN) and Dicerna Pharmaceuticals, Inc. (DRNA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ANCN and DRNA operate in Major Pharmaceuticals (Health Care), so they compete in similar markets.
- DRNA carries a market cap of $2.96B.
- DRNA has more recent analyst coverage (14 ratings vs 0 for ANCN).
- Company
- Anchiano Therapeutics Ltd.
- Dicerna Pharmaceuticals, Inc.
- Price
- -
- $38.23+0.61%
- Market cap
- -
- $2.96B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Major Pharmaceuticals
- Major Pharmaceuticals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- 2014
- News (4w)
- 0
- 0
- Recent ratings
- 0
- 14
Dicerna Pharmaceuticals, Inc.
Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercializing of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare, cardiometabolic, viral, and chronic liver diseases; complement-mediated diseases; and neurodegenerative diseases and pain. Its principal development programs include nedosiran for the treatment of primary hyperoxaluria; RG6346 for the treatment of chronic hepatitis B virus infection; belcesiran for the treatment of deficiency-associated liver disease; and DCR-AUD for the treatment of alcohol use disorder. Dicerna Pharmaceuticals, Inc. has strategic collaborations with Novo Nordisk A/S, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
Latest ANCN
- SEC Form 8-K/A filed by Anchiano Therapeutics Ltd.
- SEC Form 4: Ltd. Gp Israel Orbimed was granted 288,170 units of American Depository Shares
- SEC Form 4: Peter Thiel bought $0 worth of American Depositary Shares (230,536 units at $0.00)
- SEC Form 3: Peter Thiel claimed ownership of 877,973 units of American Depositary Shares
- Anchiano Announces Shareholder Approval of the Merger with Chemomab and Prices $45.5M Private Financing
- SEC Form 4 filed by Stanislav Polovets
- SEC Form 3 filed by Stanislav Polovets
- SEC Form 3 filed by Andrew Fine
- SEC Form 4 filed by Harris Neil Cohen
- SEC Form 3: Harris Neil Cohen claimed ownership of 62,110 units of Ordinary Shares
Latest DRNA
- Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer
- SEC Form 15-12B filed by Dicerna Pharmaceuticals, Inc.
- SEC Form EFFECT filed by Dicerna Pharmaceuticals, Inc.
- SEC Form EFFECT filed by Dicerna Pharmaceuticals, Inc.
- SEC Form EFFECT filed by Dicerna Pharmaceuticals, Inc.
- SEC Form EFFECT filed by Dicerna Pharmaceuticals, Inc.
- SEC Form 4: Koppel Adam closing all direct ownership in the company
- SEC Form 4: Zeng Ling closing all direct ownership in the company
- SEC Form 4: Weissman James B closing all direct ownership in the company
- SEC Form 4: Smith Cynthia closing all direct ownership in the company